Holen Sie sich die Stockscreener-App
4.75
1.50%
0.07
Schlusskurs vom Vortag:
$4.68
Offen:
$4.74
24-Stunden-Volumen:
2.22M
Relative Volume:
0.33
Marktkapitalisierung:
$1.67B
Einnahmen:
$143.05M
Nettoeinkommen (Verlust:
$-145.99M
KGV:
-11.09
EPS:
-0.4282
Netto-Cashflow:
$-134.06M
1W Leistung:
-4.04%
1M Leistung:
-18.10%
6M Leistung:
-1.45%
1J Leistung:
+25.99%
1-Tages-Spanne:
$4.67
$4.855
1-Wochen-Bereich:
$4.61
$5.06
52-Wochen-Spanne:
$3.36
$9.75
Nuvation Bio Inc Stock (NUVB) Company Profile
Firmenname
Nuvation Bio Inc
Sektor
Branche
Telefon
332-208-6102
Adresse
1500 BROADWAY, NEW YORK
Compare NUVB vs VRTX, MRNA, REGN, ARGX, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NUVB
Nuvation Bio Inc
|
4.75 | 1.67B | 143.05M | -145.99M | -134.06M | -0.4282 |
VRTX
Vertex Pharmaceuticals Inc
|
509.10 | 129.04B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
238.23 | 95.11B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
800.96 | 82.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
847.89 | 53.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
371.80 | 42.06B | 5.76B | 514.49M | 1.10B | 4.4813 |
Nuvation Bio Inc Stock (NUVB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-09-30 | Eingeleitet | Citigroup | Buy |
| 2026-08-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2026-08-18 | Eingeleitet | JP Morgan | Overweight |
| 2025-11-24 | Eingeleitet | Truist | Buy |
| 2025-11-19 | Eingeleitet | B. Riley Securities | Buy |
| 2025-09-30 | Eingeleitet | Jefferies | Buy |
| 2025-04-23 | Eingeleitet | Citizens JMP | Mkt Outperform |
| 2024-03-27 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-26 | Hochstufung | BTIG Research | Neutral → Buy |
| 2023-01-06 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-02 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2022-08-02 | Herabstufung | BTIG Research | Buy → Neutral |
| 2022-05-04 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-15 | Fortgesetzt | BTIG Research | Buy |
| 2021-04-06 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-03-08 | Eingeleitet | BMO Capital Markets | Outperform |
| 2021-03-08 | Eingeleitet | BTIG Research | Buy |
| 2021-03-08 | Eingeleitet | Cowen | Outperform |
| 2021-03-08 | Eingeleitet | Jefferies | Buy |
| 2021-03-08 | Eingeleitet | Wedbush | Outperform |
Alle ansehen
Nuvation Bio Inc Aktie (NUVB) Neueste Nachrichten
3 Promising Penny Stocks With Market Caps Over $200M - Simply Wall Street
Nuvation Bio Inc. (NUVB) Stock Price, News, Quote & History - Yahoo! Finance Canada
Nuvation Bio Inc. (NUVB) stock price, news, quote and history - Yahoo Finance Singapore
Nuvation Bio Inc. (NUVB) stock price, news, quote and history - Yahoo Finance UK
What Makes Nuvation Bio (NASDAQ:NUVB) Stand Out in Nasdaq Biotech? - Kalkine Media
Elite Penny Stocks To Watch In October 2026 - Simply Wall Street
Citigroup Initiates Nuvation Bio at Buy With $12 Price Target - Moomoo
Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE) - Seeking Alpha
Citigroup Initiates Nuvation Bio at Buy With $12 Price Target - Yahoo Finance
Nuvation Bio Inc. (NUVB): Investor Outlook With A 115.82% Potential Upside - DirectorsTalk Interviews
Why Is Nuvation Bio Stock Gaining Thursday? - Benzinga
Nuvation Bio stock gains on FDA label update for IBTROZI - Investing.com
Nuvation Bio Inc. (NUVB) latest stock news and headlines – Yahoo Finance - Yahoo Finance Singapore
Nuvation Bio stock rises on Ibtrozi label update (NUVB:NYSE) - Seeking Alpha
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung Cancer - PR Newswire
Nuvation Bio Inc. (NYSE:NUVB) Wins FDA OK To Add ~50-Month DOR To IBTROZI Label - TradingView
Nuvation Bio (NUVB) Reports IBTROZI Efficacy Across ROS1 Lung Cancer Subgroups - Yahoo Finance
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung Cancer - PR Newswire
Nuvation Bio (NUVB) Stock Looks Stretched Despite Its 354% Three Year Run - webull.com
NUVB: IBTROZI dominates ROS1 with best-in-class efficacy, while safusidenib advances across glioma subtypes - TradingView
Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com
NUVB: IBTROZI’s superior efficacy and safety drive rapid market share gains, with a strong pipeline advancing - TradingView
Nuvation Bio at 12th Annual Cantor Fitzgerald Global Healthcare Conference: pipeline gains - Investing.com Canada
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com Canada
Nuvation Bio at citigroup biopharma summit: growth rests on three pillars - Investing.com UK
NUVB: IBTROZI and safusidenib drive growth with best-in-class efficacy and expanding global opportunities - TradingView
NUVB: IBTROZI and safusidenib drive strong growth, with major clinical and commercial milestones ahead - TradingView
Jim Cramer sends strong 5-word message on surging biotech stock - Yahoo Finance
Jim Cramer sends strong 5-word message on surging biotech stock - thestreet.com
Jim Cramer: This Health Care Stock Is Pure Spec, The Only Neocloud I Like Is... - Benzinga
Cramer's lightning round: Nuvation Bio 'is a pure spec' - CNBC
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Yahoo Finance
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect? - Zacks Investment Research
Nuvation Bio to Participate in Upcoming Investor Conferences - Investing News Network
Nuvation Bio to Participate in Upcoming Investor Conferences - PR Newswire
Nuvation Bio (NUVB) Upgraded to Buy: Here's Why - Yahoo Finance
Nuvation Bio downgraded to Hold after 200% rall... - Pluang
NUVB|Nuvation Bio Inc|Price:7.100|Chg%:+0.340 - TradingKey
Nuvation Bio | 4: Statement of changes in beneficial ownership of securities-Officer Hattersley Gary - Moomoo
Nuvation Bio (NUVB) CSO sells 100K shares at $7.09 - Stock Titan
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com Canada
Why is Nuvation Bio stock rallying today? By Investing.com - Investing.com UK
Nuvation Bio stock rises after Cantor starts at Overweight - Investing.com
Nuvation Bio rises as Cantor initiates at overweight - Seeking Alpha
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com Canada
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating By Investing.com - Investing.com India
Cantor Fitzgerald initiates Nuvation Bio stock with overweight rating - Investing.com
JPMorgan sees 100% upside in overlooked cancer drug stock - thestreet.com
FDA grants Nuvation fast-track status for safusidenib in IDH1-mutant glioma - AllSci
Finanzdaten der Nuvation Bio Inc-Aktie (NUVB)
Umsatz
Nettogewinn
Free Cashflow
ENV
Nuvation Bio Inc-Aktie (NUVB) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER |
Aug 19 '26 |
Sale |
7.09 |
100,000 |
709,240 |
0 |
| GARY HATTERSLEY | Officer |
Aug 19 '26 |
Proposed Sale |
6.96 |
100,000 |
696,000 |
0 |
| Sauvage Philippe | Chief Financial Officer |
Jul 15 '26 |
Option Exercise |
2.17 |
40,000 |
86,800 |
54,131 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Option Exercise |
2.93 |
63,000 |
184,590 |
116,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER |
Jun 23 '26 |
Sale |
6.02 |
63,000 |
379,191 |
53,000 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Option Exercise |
2.17 |
47,668 |
103,440 |
60,341 |
| Sauvage Philippe | Chief Financial Officer |
Jun 23 '26 |
Sale |
6.01 |
47,668 |
286,370 |
12,673 |
| STACY MARKEL | Officer |
Jun 23 '26 |
Proposed Sale |
5.76 |
125,000 |
720,000 |
0 |
| KERRY WENTWORTH | Officer |
Jun 23 '26 |
Proposed Sale |
5.76 |
63,000 |
362,880 |
0 |
| PHILIPPE SAUVAGE | Officer |
Jun 23 '26 |
Proposed Sale |
5.76 |
47,668 |
274,568 |
0 |
2.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):